TBD

TBA

TBA

Chris Riley is a leader on the Strategic Insights team at H1, specializing in addressing clients' unique needs across the pharmaceutical product lifecycle. In his role, Chris serves as a key liaison between clients and product teams, ensuring that H1’s clinical offerings leverage the latest advancements in AI and DE&I performance data to drive more diverse and effective clinical trials.

With over 15 years of scientific expertise, Chris now focuses on bringing clinical solutions to market that promote equitable patient access to trials, spanning areas such as protocol optimization, site selection, and principal investigator identification.

Chris holds a Bachelor of Science in Biochemistry from the College of Charleston and a PhD in Biochemistry from the University of Texas at Austin.

Breck's approach is centered on understanding and meeting client needs. With over 30 years of experience in healthcare technologies, he shares his expertise in product realization, from hands-on development and engineering to project planning and management, operational leadership, and strategizing for commercialization. He values his clients and ensures their needs are met through collaborative, efficient delivery of solutions.

Sean Stanton is the CEO and Co-founder of K2 Medical Research. He has dedicated the last 28 years of his career to creating successful, high-performing research sites. In this latest endeavor, Sean leads a dynamic team of dedicated researchers in connecting the innovative solutions of clinical research to the health problems in our country.

Sean has led the start-up of 26 clinical trial sites, six inpatient hospitals, and 19 outpatient clinics. More than 5,000 clinical trials have been conducted at these sites, leading to more than 50 drug approvals in therapeutic areas including general medicine, mental health, neurodegenerative disease, oncology, vaccine, women’s health, diabetes, pain, heart disease, and sleep disorders.

Sean brings innovative thinking and unique problem-solving skills to clinical research in all aspects of site practices, from purchasing and resourcing, to the use of benchmarking and metrics in business planning to guide strategic clinical trial practice growth. He is frequently sought as an industry expert to speak on topics including building successful clinical research sites, patient recruiting, particularly difficult to recruit populations and decreasing time to complete research studies, protocol design, site selection, patient reported outcomes and other areas. He has advised hospitals and institutions on research site growth strategy and mergers and acquisitions.

After graduating from the University of Cincinnati he joined a team of clinical trial industry experts and has been in this industry ever since. Sean’s passion for clinical research and organizational leadership are a driving force in his life- he works hard every day to make clinical trials a care option for all people.

He is a member of the Board of Trustees at Western University of Health Sciences in Pomona, CA., founding member of the DAVOS Alzheimer’s Collaboration (DAC), a board member of the Alzheimer’s Dementia Resource Center in Central Florida, Strategic Advisor to the Global Alzheimer’s Platform, a member of CEO, and sits on the board of directors for Young Presidents Organization (YPO).

Dr. Janelle A. Sabo is a recognized leader in drug development, clinical research, and product delivery.  Her unique background has driven a strong patient focus and desire to find innovative ways to deliver new therapies faster to patients and the global medical community.

Janelle is currently Senior Vice President of Clinical Capabilities at Eli Lilly and Company. Her organization encompasses over 1500 employees across the globe delivering over 500 clinical trials. Clinical Capabilities is responsible for the delivery of clinical studies, including investigator engagement, trial capabilities, clinical labs and systems, clinical trial material, ancillaries and related supply planning/delivery, clinical development systems, clinical research services, clinical innovation and digital health.

Janelle started her career in clinical development and has held key leadership roles across clinical development, chemistry manufacturing and controls, portfolio management and led drug development and brand teams from early discovery to launch. In each role, Dr. Sabo has driven innovative designs, delivery and transformation leading to accelerated drug development and savings over a $1 billion dollars. As an example, she transformed the clinical supply chain to be end to end resulting in 15-20% faster cycle times and a savings of over $200M. During the COVID-19 pandemic, Janelle led the COVID-19 Therapeutics Platform which delivered multiple neutralizing antibodies in under 12 months from discovery to market and utilized novel approaches for clinical and commercial delivery. 

Dr. Sabo recipient of multiple awards at Eli Lilly and in the industry.  She has been named to the Global Product Development President’s Council, twice honored with the Lilly Research Laboratories President’s award, selected as the University of Missouri Pharmaceutical Industry Alumni of the Year and the Pharma We Work for Health award. She has served on dean’s advisory boards, including Butler University and UMKC Dean’s Advisory Board. Janelle holds a Doctorate of Pharmacy from the University of Missouri, Global Executive MBA from Georgetown University, and a Global Executive MBA from ESADE- Barcelona, Spain.

Dr. Sabo is a guest lecturer at several universities and colleges of pharmacy on drug development an has spoken at conferences within the pharmaceutical industry and was the keynote graduation speaker for the UMKC School of Pharmacy. To connect with her, visit @  https://www.linkedin.com/in/janelle-sabo-16248114 .

Dr. Yngve Mikkelsen is an experienced physician, health economist, and biotechnology executive with over 25 years of leadership in pharma, medtech, and translational R&D. He currently serves as Chief Medical Officer at AlgiPharma, where he leads the company’s clinical, regulatory, and partnering strategy for novel alginate oligosaccharide technologies. Dr. Mikkelsen previously held senior roles at Pfizer, Biogen, Akershus University Hospital, and the Norwegian Medical Association, successfully leading multiple regulatory programs through the FDA and EMA. His work focuses on advancing non-injectable delivery of complex therapeutics, including peptides and lipid nanoparticles, via mucosal and oral routes. Yngve also holds a Doctor of Business Administration from Cranfield University, an MSc in Health Economics from the London School of Economics, and an Applied Data Science certificate from MIT. He is a regular contributor at ISPOR and serves on the expert review panel of the Norwegian Research Council.

Charles has more than 30 years experience in the drug delivery industry. He has been employed as a Project Leader for the last five years at Chiesi, an Italian family owned pharmaceutical company with a turnover of ~€3.5bn. Chiesi is a leader in respiratory medicines and has an expanding range of rare disease products which utilize a range of delivery technologies. Charles is working on a range of projects requiring the administration of small molecules, peptides and proteins.

Much of Charles’ career has focused on novel injectable technologies. Following an engineering degree and PhD, Charles joined PowderJect Pharmaceuticals and saw it grow from 4 to >1,000 employees. He then founded and was CEO of Glide Pharma for 12 years before working as an independent consultant with a portfolio of companies which were either developing a proprietary drug delivery technology or were selecting a delivery technology for their novel compound.

Chris Cooper is a Device Engineering Lead at Gilead Sciences, where he supports the development of long-acting injectable drug delivery systems for HIV prevention. He specializes in design control, combination product development, and supplier collaboration. Prior to Gilead, Chris led the technical development of a fully customized on-body delivery system for subcutaneous administration of a biologic oncology therapy, learning key insights into the use of wearable systems for extended drug delivery. Earlier in his career, he supported commercial biologics manufacturing at Bristol Myers Squibb, contributing to the launch and lifecycle management of immuno-oncology therapies. Chris holds an M.Eng. in Bioengineering from UC Berkeley and a B.S. in Chemical Engineering from UCLA. He brings a multidisciplinary background in drug-device development and is passionate about advancing patient-centered delivery technologies and enabling patient access to breakthrough therapies.

After starting her career in New Jersey at Merck as a Research Biologist, Karen Lowitz changed direction and moved into Regulatory Affairs. In 2009, she relocated to beautiful Colorado where she joined Sandoz with responsibility for generic drug regulatory submissions. Most of her professional time in CO was with Terumo BCT supporting blood collection and cell processing devices, which provided opportunities to manage a team and travel to Japan, Northern Ireland, Vietnam, and India to support combination product manufacturing. In 2023, she joined Biogen to work on a Phase 3 clinical therapy to be presented in multiple drug/device combinations. In 2025, sunny California became her home, and she continues to support the complex program for which Biogen plans to commercialize. Global regulation of combination products is ever evolving, which is why it is exciting to work in this space.

With a keen business mindset and over 25 years of experience in pharmaceutical development and GMP manufacturing, Okke Franssen excels at forging strategic partnerships and driving commercial growth. Throughout his career—spanning start- ups, biotech, and large pharmaceutical organizations—he has successfully led business development initiatives, negotiated complex deals, and advanced innovative injectable technologies from concept to market. Since 2015, Okke is leading Nanomi, where his expertise and visionary leadership have guided the company from laboratory innovation to GMP-compliant commercial production, attracting key pharma and biotech collaborators worldwide. Okke holds a PhD in pharmaceutics and is trained as a physical organic chemist, underpinning his commercial success with deep scientific expertise.